Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 20/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16211738 | 0.83 | CNR2 (0.70) | CNR2 | |
| SCHEMBL14973764 | 0.80 | CNR2 (0.58) | CNR2 | |
| SCHEMBL20970218 | 0.80 | CNR2 (0.58) | CNR2 | |
| SCHEMBL14911671 | 0.79 | CNR2 (0.54) | CNR2 | |
| SCHEMBL20611053 | 0.78 | CNR2 (0.61) | CNR2 | |
| SCHEMBL14973988 | 0.78 | CNR2 (0.52) | CNR2 | |
| SCHEMBL14973978 | 0.76 | CNR2 (0.54) | CNR2 | |
| SCHEMBL23544261 | 0.74 | CNR2 (0.56) | CNR2 | |
| SCHEMBL16222478 | 0.73 | CNR2 (0.58) | CNR2 | |
| SCHEMBL16555007 | 0.72 | CNR2 (0.49) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3943497-A1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES AS CB2 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2022-01-26 | — | — | EP | disclosed |
| EP-3483163-B1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES AS CB2 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2021-06-23 | — | — | EP | disclosed |
| EP-3483163-A2 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES AS CB2 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2019-05-15 | — | — | EP | disclosed |
| EP-3041843-B1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES AS CB2 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2019-01-02 | — | — | EP | disclosed |
| US-9593123-B2 | Triazolo[4,5-D]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593123-B2 | Triazolo[4,5-D]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-03-14 | — | — | US | disclosed |
| EP-3041843-A1 | NOVEL TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-20160168158-A1 | NOVEL TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160168158-A1 | NOVEL TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-06-16 | — | — | US | disclosed |
| EP-2782915-B1 | [1,2,3]TRIAZOLO[4,5-d]PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2015-09-30 | — | — | EP | disclosed |
| EP-2782915-B1 | [1,2,3]TRIAZOLO[4,5-d]PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2015-09-30 | — | — | EP | disclosed |
| US-9067943-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067943-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| WO-2015032769-A1 | NOVEL TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-03-12 | — | — | WO | disclosed |
| WO-2015032769-A1 | NOVEL TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-03-12 | — | — | WO | disclosed |
| EP-2782915-A1 | [1, 2, 3]TRIAZOLO [4, 5 -D]PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-01 | — | — | EP | disclosed |
| US-20130137676-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137676-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-30 | — | — | US | disclosed |
| WO-2013076182-A1 | [1, 2, 3]TRIAZOLO [4, 5 -D] PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013076182-A1 | [1, 2, 3]TRIAZOLO [4, 5 -D] PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137676-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | TYMS, TBXA2R, TYMP | CNR2 135/4885 |
| US-20160168158-A1 | NOVEL TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | TYMS, TYMP, P2RX4 | CNR2 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.